# Eikon Therapeutics Inc. (EIKN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $10.86, market value $588 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Eikon Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -48.7%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 36.9%**. 36.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): 17.1%**. Earnings per share rose 17.1%.

## Financial health
- **Current ratio: 6.34** (quick 6.34). Current assets cover the next year's liabilities 6.34 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Eikon Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Eikon Therapeutics Inc.; the consensus is buy, with an average price target of $24.60 (+127% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -37.6%** (37.5% above the low). Trading 38% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 2.21** (volatility 91%). Beta of 2.21 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EIKN · Page: https://foliofundamentals.com/stocks/eikn

Not investment advice.